Clinical trials
Lymphoma clinical trials
Cancer of the lymphatic system, part of the body’s immune defenses. We’re tracking 1,332 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05501379Recruiting
Track activity in cancer patients during treatment
This study compares how physical activity answers on a questionnaire match what a motion tracker measures. It may help researchers understand activity levels in people with lymphoma, colorectal, or pancreatic cancer during treatment.
GreifswaldAges 18 years+ - NCT06363994RecruitingPhase 3
Study of orelabrutinib plus BR for untreated mantle cell lymphoma
This trial tests a new combination of drugs (orelabrutinib plus BR) compared to BR alone for people with newly diagnosed mantle cell lymphoma who have not had treatment before. It may be an option if you are older or not able to have a stem cell transplant.
BeijingAges 60 years+ - NCT07538635RecruitingPhase 2
CAR-T cells plus stem cell transplant for aggressive lymphoma
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
Hangzhou, ZhengjiangAges 18 years+ - NCT06756152RecruitingPhase 2/Phase 3
Preventing GVHD after transplant for blood cancers in children and young adults
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
MoscowAges 1 day–21 years - NCT07528352RecruitingPhase 1
Radiation Plus Antibody Therapy for Difficult-to-Treat Lymphoma
This trial tests a combination of radiation therapy to specific tumor sites followed by a bispecific antibody (a type of immunotherapy that targets cancer cells). It's designed for people with diffuse large B-cell lymphoma that has not responded to or has come back after at least two prior treatments.
Salt Lake City, UtahAges 18 years+ - NCT07522905Recruiting
Virtual Movement Therapy for Kids With Leukemia in Remission
This study tests a fun virtual movement program where children who have finished leukemia treatment exercise together with a healthy friend online. The goal is to help improve their physical strength, coordination, and social skills after cancer treatment.
BratislavaAges 5–12 - NCT06756321RecruitingEarly Phase 1
CAR T-cell therapy for relapsed blood cancers
This study tests a new type of therapy called CAR T-cells for people with blood cancers that have returned or not responded to standard treatments. CAR T-cells are made from your own immune cells and are trained to find and kill cancer cells.
Nantong, JiangsuAges 18–70 - NCT06758713RecruitingPhase 1
Gene-therapy treatment for blood cancers: safety and early effects
This trial tests a new kind of gene therapy (fourth-generation CAR-T) for several types of blood cancers including lymphoma, leukemia, and myeloma. It aims to see if the treatment is safe and starts to work against the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07509450Recruiting
Fecal transplant study for CAR-T and stem cell transplant patients
This pilot study tests whether giving a fecal microbiota transplant before standard CAR-T therapy (for B-cell lymphoma) or reduced-intensity stem cell transplant (for AML or high-risk MDS) can improve treatment outcomes. It aims to see if restoring gut bacteria helps reduce complications.
Toronto, OntarioAges 18 years+ - NCT07514169RecruitingPhase 2
New Combination Drug for Older Adults with B-Cell Lymphoma
This study tests whether a new three-drug combination (Pola-ZR-Glo) works safely and effectively for older adults with a type of blood cancer called large B-cell lymphoma who cannot or prefer not to receive standard chemotherapy. The goal is to find a gentler treatment option for frail or elderly patients.
ShanghaiAges 70 years+ - NCT07499271RecruitingPhase 2
Targeted therapy for newly diagnosed DLBCL with TP53 mutation
This trial tests a targeted therapy designed to match the specific genetic subtype of DLBCL that has a TP53 mutation. It may offer a more effective treatment option for people whose cancer has this genetic change.
Suzhou, JiangsuAges 18–70 - NCT07507318RecruitingPhase 2
Low-dose chemo to prevent relapse in high-risk DLBCL patients
This trial tests a low-dose chemotherapy pill (chidamide) for people with a certain high-risk type of DLBCL that still has signs of cancer in the blood after initial treatment. The goal is to keep the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07493109RecruitingPhase 3
Maintenance treatment for hepatitis B-related lymphoma after initial therapy
This trial tests whether the drug chidamide, taken after initial successful treatment, can help prevent relapse in people with a type of lymphoma (diffuse large B-cell lymphoma) who also have chronic hepatitis B. Participants must have achieved complete remission after six cycles of standard chemotherapy (R-CHOP).
Changchun, JilinAges 18–80 - NCT07493148RecruitingPhase 2
Chidamide and chemo for older adults with double-expressor DLBCL
This trial tests a combination of the targeted drug chidamide with a gentler chemotherapy (R-mini CHOP) followed by maintenance therapy for people aged 70 or older with a specific type of DLBCL that has both MYC and BCL2 proteins. It aims to improve outcomes while reducing side effects.
Changchun, JilinAges 70 years+ - NCT07494565RecruitingPhase 2
Celecoxib plus standard chemo for CD5+ DLBCL
This trial tests whether adding celecoxib (an anti-inflammatory drug) to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific, hard-to-treat type of diffuse large B-cell lymphoma (DLBCL) that is CD5-positive. It's for people who are newly diagnosed and have advanced disease.
Guangzhou, GuangdongAges 18–80 - NCT07474051Enrolling by invitation
Long-term follow-up for CAR-T cell therapy patients
This study tracks people who received a specific CAR-T cell therapy made by AvenCell. The goal is to monitor their health over time to better understand long-term effects.
BerlinAges Any age - NCT07472972Recruiting
Personalized risk tracking for CD19 CAR T therapy
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
Zurich, Canton of ZurichAges Any age - NCT06783816Recruiting
New immune cell therapy for blood cancers
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
Taiyuan, ShanxiAges Any age - NCT04807881RecruitingPhase 1
Study of keynatinib for certain hard-to-treat lymphomas
This Phase 1 trial tests keynatinib, a new medicine, in people with specific types of lymphoma that have returned or not responded to earlier treatment. It aims to find a safe dose and see whether it can shrink tumors in the brain or elsewhere in the body, depending on the group.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07456371RecruitingPhase 1
PIC1 injection for relapsed or refractory B-cell lymphoma
This trial tests a new treatment called PIC1 for people with certain types of B-cell lymphoma that have come back after treatment or stopped responding. PIC1 is a type of immunotherapy that helps your immune system attack the cancer cells.
Wuhan, HubeiAges 18–75 - NCT05654675Recruiting
Scan method study for measuring tumor sugar use on PET
This study checks whether a specific analysis method (called FUR) can better measure how much “sugar” from PET scans is used by tumors. It uses regular PET/CT scans you may already get as part of standard care, and compares how the measurements work.
Maastricht, LimburgAges 18 years+ - NCT07450040Enrolling by invitation
Tislelizumab plus chemo for early-stage NK/T-cell lymphoma
This trial tests a combination of the immunotherapy drug tislelizumab with two chemotherapy drugs (gemcitabine and peraspartase) for people with newly diagnosed stage I or II NK/T-cell lymphoma. The goal is to see if this combination works well and is safe.
Shanghai, ChinaAges 18–70 - NCT07453095RecruitingPhase 2
Glofitamab for mantle cell lymphoma after CAR T-cell therapy
This trial tests a new drug called glofitamab for people with mantle cell lymphoma (MCL) whose cancer did not respond or came back after CAR T-cell therapy. Glofitamab is a type of immunotherapy that helps your immune system fight the cancer.
AlessandriaAges 18 years+ - NCT07451652RecruitingPhase 2
Low dose epcoritamab plus chemotherapy for relapsed lymphoma
This trial tests a combination of a lower dose of the immunotherapy drug epcoritamab with standard chemotherapy (GemOx) for people with a type of lymphoma called DLBCL that has come back or not responded to previous treatment. The goal is to see if this combination can help get the lymphoma under control before a stem cell transplant (using your own cells).
Monterrey, Nuevo LeónAges 18–65
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma?
- Yes. Clin2 currently lists 1,332 recruiting lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.